Partnering & Drug Development
Life science dealmaking is an ongoing process. EBD Group brings together business development execs from pharma, biotech and investment through our partnering events and online community (partnering360).
Biotechs successfully navigate alternative paths to financing
Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...
Can pharma afford to cure patients instead of treating them?
Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...
Mounting uncertainty threatens research and innovation in medicines
Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...
POLs: Patient opinion leaders emerge as key to success in orphan drug designation
Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...
Facing increased complexity, oncology trial sites tighten up procedures
Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...
BIO-Europe Spring 2017 kicks off this week in Barcelona
Innovation in an uncertain world
How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? Read more »
Report gives substance to fast-paced scientific discoveries in microbiome
Guest post by Eric de La Fortelle, Venture Partner at Seventure Partners Microbes are everywhere, and apart from the occasional pathogen, they are a positive force for health maintenance. Indeed...
2016 – A Year in Review for Advanced Therapies
Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence | Informa The past year saw intensifying dialogue on how to assess the value of and...
Stirring the Pot for Entrepreneurship in European Tech Transfer
Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...
World RARE Disease Day shines a light on rare disease community
Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world. World RARE Disease Day is an...
Barcelona biotech companies shine light on regional entrepreneurship
Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....
Increase the value of your asset: Think with the end in mind
Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...
What’s the deal with Immuno-oncology partnering?
Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir
Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health
Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017
An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia